VEGFA and cancer: Despite anti-VEGF therapy for mCRC becoming widely adopted, this still presents several challenges including anti-angiogenic therapy resistance, which is thought to be largely correlated with tumour endothelial cell (TEC) heterogeneity.202 Preclinical studies have shown that in these patients, tumours are able to cultivate compensatory mechanisms, which consequently restore angiogenic density and therefore, cancer progression.